However, biomarkers that are useful for targeted and immunotherapy prediction in other cancers, such as programmed death ligand 1 (PD-L1) and tumor mutation burden (TMB), have no established predictive role in HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.